Online inquiry

IVTScrip™ mRNA-Anti-FZD1&FZD2&FZD5&FZD7&FZD8, OMP-18R5(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12667MR)

This product GTTS-WQ12667MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets FZD1&FZD2&FZD5&FZD7&FZD8 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_003505.2; NM_001466.4; NM_003468.4; NM_003507; NM_031866.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8321; 2535; 7855; 8324; 8325
UniProt ID Q9UP38; Q14332; Q13467; O75084; Q9H461
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FZD1&FZD2&FZD5&FZD7&FZD8, OMP-18R5(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ12667MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13177MR IVTScrip™ mRNA-Anti-TNFRSF4, PF-04518600(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PF-04518600
GTTS-WQ7423MR IVTScrip™ mRNA-Anti-EGFR, GA201(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GA201
GTTS-WQ8430MR IVTScrip™ mRNA-Anti-HSP90, HSP90mab(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HSP90mab
GTTS-WQ2287MR IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ALXN1007
GTTS-WQ126MR IVTScrip™ mRNA-Anti-EGFR, 11F8(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA 11F8
GTTS-WQ11497MR IVTScrip™ mRNA-Anti-MET, MetMAb(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MetMAb
GTTS-WQ10005MR IVTScrip™ mRNA-Anti-FGF23, KRN-23(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA KRN-23
GTTS-WQ2692MR IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG 785
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW